Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
11/2005
11/30/2005EP1257299B9 Radioactive therapeutic liposomes
11/30/2005EP1192268B1 Nucleic acid binding of multi-zinc finger transcription factors
11/30/2005EP1192181B1 Modulation of angiogenesis by using the anti-angiogenic angiotensin-7 and polynucleotides encoding therefor for the treatment of tumor
11/30/2005EP1185306B1 Use of viral vectors and charged molecules for gene therapy
11/30/2005EP1176981B1 Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
11/30/2005EP1173153B1 Oral pharmaceutical compositions containing long-chain triglycerides and lipophilic surfactants
11/30/2005EP1169327B1 L-arabino-disaccharides of anthracyclines, processes for their preparation, and pharmaceutical compositions containing them
11/30/2005EP1144372B1 Sulphohydroxamic acids and sulphohydroxamates and their use as mek inhibitors
11/30/2005EP1140786B1 Reductive alkylation of secondary amines with hydrosilane
11/30/2005EP1079832B1 Use of vitamin pp compounds
11/30/2005EP0963200B9 Compositions for inhibition of angiogenesis comprising thalodomide and a nsaid
11/30/2005EP0920424B1 Non-peptide bombesin receptor antagonists
11/30/2005EP0891377B1 Inhibitor and stimulator of haematopoietic stem cell proliferation and uses thereof
11/30/2005EP0491793B1 2'-deoxy-4'-thioribonucleosides as antiviral and anticancer agents
11/30/2005CN1703513A Tuberculosis vaccines including recombinant bcg strains expressing alanine dehydrogenase, serine dehydratase and/or glutamine synthetase
11/30/2005CN1703504A Use of L-alpha-lysophosphatidylcholine to obtain the differentiation of monocytes in mature dendritic cells in vivo$
11/30/2005CN1703420A Promoters exhibiting endothelial cell specificity and methods of using same
11/30/2005CN1703414A Novel imidazopyridines as cyclin dependent kinase inhibitors
11/30/2005CN1703405A Aminobenzamide derivatives as glycogen synthase kinase 3 beta inhibitors
11/30/2005CN1703393A Spiro compounds, medicinal compositions containing the same and intermediates of the compounds
11/30/2005CN1703247A Anti-neovasculature preparations for cancer
11/30/2005CN1703230A Antitumor agent containing lactic acid oligomer mixture
11/30/2005CN1703229A Compositions and methods for treatment of prostate and other cancers
11/30/2005CN1703226A Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonates, a cox-2 inhibitor and a taxol
11/30/2005CN1703225A Combination therapy with gemcitabine and zd6126
11/30/2005CN1703223A Use of the quinazoline derivative zd6474 combined with gemcitabine and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability
11/30/2005CN1703217A Use of epothilone derivatives for the treatment of hyperparathyroidism
11/30/2005CN1703216A Epothilone derivatives for the treatment of multiple myeloma
11/30/2005CN1703212A Use of a combination of dppe with other chemotherapeutic agents for the treatment of breast cancer
11/30/2005CN1701816A Anti-tumor agent using interleukin-23 gene
11/30/2005CN1701814A F1K-1 is a receptor for vascular endothelial growth factor
11/30/2005CN1229502C Fermentative preparation process for cytostatics and crystal form thereof
11/30/2005CN1229498C Recombinant ribonuclease proteins
11/30/2005CN1229496C Method and compositions for inducing tumor-specific cytotoxicity
11/30/2005CN1229391C Antibody of human gastrointestinal epithelial tumor antigen related to alpha 6 beta 4 integrin
11/30/2005CN1229388C N-terminal modified protein compositions and methods therefor
11/30/2005CN1229382C Hemisynthetic method and intermediate thereof
11/30/2005CN1229374C Substituted bisindolylmaleimides for inhibition of cell proliferation
11/30/2005CN1229371C Benzopyranyl guanidine derivtives, process for preparation thereof and pharmaceutical compositions containing them
11/30/2005CN1229370C Novel derivatives of flavones, xanthones and coumarins
11/30/2005CN1229364C Intermediates and methods useful in the semisynthesis of paclitaxel and analogs
11/30/2005CN1229353C Method and compositions utilizing quinazolinones
11/30/2005CN1229349C Pyridine-3-carboxylic acid derivative
11/30/2005CN1229344C Farnesyl transferase inhibitors
11/30/2005CN1229343C Chemotactic factor receptor active regulator
11/30/2005CN1229339C Compounds inhibiting angiogenesis and tumor growth, pharmaceutical preparation containing same and pharmaceutical use thereof
11/30/2005CN1229142C NSAID and EFGR kinase inhibitor contg. compsn. for treatment or inhibition of colonic polyps and colorectal cancer
11/30/2005CN1229137C New therapeutic uses of SMR1 peptides
11/30/2005CN1229135C Chinese medicinal composition for treating lung cancer, preparing method and quality controlling method thereof
11/29/2005US6969765 Photosensitizer and method for production thereof
11/29/2005US6969729 An indole or benz(g)indole-2,3-dione-3-oxime compounds; therapeutic treatment of respiratory disorders, urogenital disorders, cardiovascular disorders, brain and psychological disorders, gastrointestinal disorders
11/29/2005US6969728 Antiinflammatory agents
11/29/2005US6969723 preferably antagonists used in the therapeutic and/or preventive treatment of disfunctions of the heart, kidney, respiratory system, central nervous system
11/29/2005US6969720 2,6,9-trisubstituted purine derivatives which are inhibitors of cyclin/cdk (cyclin dependent kinases) complexes
11/29/2005US6969719 Such as 3-((3-bromo-4-hydroxyphenyl)methyl)-5-ethyl-7,8-dihydro-2-(tetrahydro-2H -pyran-4-yl)amino)-3H-imidazo(2,1-b) purin-4(5H)-one for treating sexual disorders
11/29/2005US6969718 17-β hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
11/29/2005US6969717 Azaindole kinase inhibitors
11/29/2005US6969714 Imidazolo-5-YL-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation
11/29/2005US6969707 For therapy or inhibiting the development of a pathology associated with peroxynitrite damage
11/29/2005US6969596 Polynucleotide encoding a human receptor tyrosine kinase
11/29/2005US6969592 Method for predicting the sensitivity to chemotherapy
11/29/2005US6969524 Interferon complex and medicinal use thereof
11/29/2005US6969517 Anticancer agents; genetic engineered fusion protein
11/29/2005US6969508 Buccal aerosol sprays or capsules using polar and non-polar solvent which provide biologically active compounds for rapid absorption through the oral mucosa, resulting in fast onset of effect
11/29/2005CA2288445C 5-oxo-pyrrolidine-2-carboxylic acid hydroxamide derivatives
11/29/2005CA2080545C Salts of hydrazones
11/29/2005CA2070799C Thioxanthenone antitumor agents
11/26/2005CA2503105A1 Use of lif in cosmetics and dermatology
11/24/2005WO2005111234A2 Methods of using zc1 and zc3 kinase substrate phosphorylation as biomarkers
11/24/2005WO2005111213A1 Target gene mimitin of myc
11/24/2005WO2005111208A1 Method of proliferating plasma cell
11/24/2005WO2005111200A1 Novel strains of reoviruses and methods of uses thereof
11/24/2005WO2005111198A1 Cancerous disease modifying antibodies
11/24/2005WO2005111082A1 Anti-tfr antibody.
11/24/2005WO2005111067A1 A novel identified oncogene with kinase-domain (nok)
11/24/2005WO2005111055A1 Novel antibiotic kigamicins and use thereof
11/24/2005WO2005111037A1 Beta-carbolines useful for treating inflammatory disease
11/24/2005WO2005111001A1 Novel fused heterocycles and uses thereof
11/24/2005WO2005110996A1 Novel cis-imidazolines
11/24/2005WO2005110487A2 Camptothecin derivatives conjugated in position 20 with integrin antagonists
11/24/2005WO2005110486A2 7-t-butoxyiminomethylcamptothecin conjugated in position 20 with integrin antagonists
11/24/2005WO2005110476A1 Method of inhibiting telomerase activity and inhibitor
11/24/2005WO2005110438A2 Methods and products related to the intracellular delivery of polysaccharides
11/24/2005WO2005110392A1 Methods of modulating flt3 activity
11/24/2005WO2005110389A1 Medicinal agent
11/24/2005US20050262577 Polypeptides and nucleic acids encoding these and their use for the prevention, diagnosis or treatment of liver disorders and epithelial cancer
11/24/2005US20050261502 2-Amino-4-(1,3-benzodioxol-5-yl)-6-benzyloxy-3,5-pyridinedicarbonitrile, acting as adenosine-receptor-selective ligands, for the prophylaxis and/or treatment of cardiovascular disorders
11/24/2005US20050261496 3-(Morpholin-4-ylsulfonyl)-5-(1,3-thiazol-2-yl)-1H-indole-2-carboxamide; inhibiting, modulating and/or regulating signal transduction of both receptor and non-receptor tyrosine kinases; anticarcinogenic, -diabetic, -arhtritic, -inflammatory agents; psoriasis; angiogenesisinhibitors; liver cirrhosis
11/24/2005US20050261363 Acetone extraction for gamboge resins for tumor purification for antitumor and anticancer agent cells with acetone extraction
11/24/2005US20050261356 Methods and compositions for the treatment of chronic lymphocytic leukemia
11/24/2005US20050261343 Anthranilamides and their use as pharmaceutical agents
11/24/2005US20050261326 Metabolites of ecteinascidin 743
11/24/2005US20050261320 Compounds and methods for the treatment of cancer
11/24/2005US20050261317 Inhibitors of human phosphatidylinositol 3-kinase delta
11/24/2005US20050261313 For angiogenesis mediated diseases; cancer; acylation, cyclization and Heck-type reduction
11/24/2005US20050261305 Cyclic protein tyrosine kinase inhibitors
11/24/2005US20050261303 e.g. (2R,5S)-4-(3-chloro-4-cyanophenyl)-N-(2-cyclopropylpyrimidin-5-yl)-2,5-dimethylpiperazine-1-carboxamide; antiandrogenic agent
11/24/2005US20050261293 Compounds which inhibit leukocyte adhesion mediated by VLA-4
11/24/2005US20050261288 Tetracyclic lactam derivatives and uses thereof
11/24/2005US20050261284 Diazinopyrimidines
1 ... 1236 1237 1238 1239 1240 1241 1242 1243 1244 1245 1246 1247 1248 1249 1250 1251 1252 1253 1254 1255 1256 ... 2211